Polymorphism of the IgH Locus Regulatory Region as a Prognostic Factor During Immune Pathologies.
NCT ID: NCT01715623
Last Updated: 2019-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
486 participants
OBSERVATIONAL
2012-10-31
2014-12-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Regarding hypersensitivities, the diversity of their clinical manifestations prompt us to focus on homogeneous groups of patients and we thus wish to concentrate on two groups of patients who are frequently referred to the hospital: severe allergies to Hymenoptera venoms and severe food allergies related to peanut allergens sensitization. These groups will be built by considering multiple clinical criteria (clinical history, severity of the manifestations, positive skin tests, and positive oral provocation tests for peanut allergens…) and biological criteria authenticating the mechanisms of the disease (high specific serum IgE, demonstration of specific basophil activation by the allergen…).
In parallel to the study in patients, we will include a large cohort of healthy controls (400 individuals), in order to be able to decipher whether correlations can be seen between:
* IgH 3'RR genotypes
* The serum accumulation of the various Ig classes, including IgG subclasses, IgA (which are sometimes depicted as protective, sometimes as tolerogenic and anti-inflammatory) and IgE (highly pro-inflammatory and responsible for hypersensitivities)
* IgG allotypes (with 6 frequent IgG haplotypes known in human and previously reported as correlated with varying levels of IgG and IgE production in normal individuals).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Distribution of Immunoglobulin Isotype in Polyclonal Hypergammaglobulinemia in Systemic and Autoimmune Diseases
NCT06054373
Role of Regulatory T Cells in Pathogenesis of Primary IgA Nephropathy
NCT00521508
Interest of Follicular Helper Lymphocytes / Regulatory Follicular Helper Lymphocytes Ratio in IgA Nephropathy
NCT05791162
IgA Nephropathy, Lymphocyte Homing and IgA Class Switch
NCT01775527
Multicenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of Progressive Forms of IgA Nephropathy
NCT02526966
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* How the 3'RR alleles are linked to IgG allotypes and corresponding IgH haplotypes?
* Is there a physiological link between 3'RR alleles and production of the various Ig classes and sub-classes?
* Is the 3'RR polymorphism connected with the risk of more severe forms of allergic diseases?
* Is the 3'RR polymorphism connected with the risk of occurrence and/or severe evolution of HSP?
* Is the oncogenicity of translocations affecting the IgH locus connected to the strength of the 3'RR allelic variants?
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Children with HSP
children with Purpura of Henoch-Schönlein with or without renal complication
a blood sample
Dosage of Ig
healthy volunteers
healthy volunteers without allergy
a blood sample
Dosage of Ig
subjects with allergy
subjects with peanut allergy or hymenoptera venom allergy
a blood sample
Dosage of Ig
lymphoma
lymphoma-proliferation with chromosome 14 translocation
a blood sample
Dosage of Ig
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
a blood sample
Dosage of Ig
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Age ≥ 18 and \< 50 years No history of allergy, haematological malignancies or immune diseases
* Subjects with allergy:
* Children:
Age ≥ 4 and \< 18 years Clinical history supporting the diagnosis of severe food allergy Peanut specific IgE (Arah2) -Adults: Age \> 18 and \< 60 years History of severe reaction after antigenic challenge Anaphylactic shock already experienced Specific IgE or positive BAT Positive prick tests
* subject with HPS:
* Children:
Age ≥ 4 and \< 18 years Henoch Schonlein Purpura (HSP) documented by Ankara 2008 criteria
-Adult: Henoch Schonlein Purpura(HSP) with renal involvement Adults ≥ 18 years,
Exclusion Criteria
* Healthy Volunteers:
Allergy known pregnancy patient under guardianship
4 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
Direction Générale de la Santé, France
OTHER
University Hospital, Limoges
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michel COGNE, MD
Role: PRINCIPAL_INVESTIGATOR
Limoges UH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Investigation Center
Limoges, , France
Nephrology
Limoges, , France
Pediatric
Limoges, , France
Pneumology
Limoges, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
I12002 PRIERR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.